{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:40:38Z","timestamp":1790894438625,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007857","name":"Foundation King Gustaf V 80-\u00e5rsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009389","name":"Promobilia foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009389","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001646","name":"Robert Bosch Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Heart and Lung Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007230","name":"Foundation King Gustaf V Jubilee Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Region Stockholm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ard.2026.02.018","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:30:39Z","timestamp":1773750639000},"page":"1180-1190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Inhibition of the type I interferon receptor pathway protects against muscle weakness induced by dermatomyositis serum"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1449-4219","authenticated-orcid":false,"given":"Suchada","family":"Kaewin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4835-5997","authenticated-orcid":false,"given":"Cecilia","family":"Leijding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7369-8452","authenticated-orcid":false,"given":"Stefano","family":"Gastaldello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1795-8319","authenticated-orcid":false,"given":"David","family":"Makari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0929-8224","authenticated-orcid":false,"given":"Yi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3338-4533","authenticated-orcid":false,"given":"Kristofer M.","family":"Andreasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"Jardemark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Dastmalchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2241-5170","authenticated-orcid":false,"given":"Begum","family":"Horuluoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3109-6207","authenticated-orcid":false,"given":"Helene","family":"Alexanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1140-6204","authenticated-orcid":false,"given":"Volker M.","family":"Lauschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-9212","authenticated-orcid":false,"given":"Ingrid E.","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4548-702X","authenticated-orcid":false,"given":"Daniel C.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ard.2026.02.018_bib0001","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/ar2139","article-title":"Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies","volume":"9","author":"Grundtman","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2026.02.018_bib0002","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaut.2013.11.005","article-title":"The clinical features, diagnosis and classification of dermatomyositis","volume":"48-49","author":"Iaccarino","year":"2014","journal-title":"J Autoimmun"},{"issue":"12","key":"10.1016\/j.ard.2026.02.018_bib0003","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1136\/ard.2005.051086","article-title":"Signs of inflammation in both symptomatic and asymptomatic muscles from patients with polymyositis and dermatomyositis","volume":"65","author":"Dorph","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2026.02.018_bib0004","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cyto.2014.11.026","article-title":"The role of type I interferons and other cytokines in dermatomyositis","volume":"73","author":"Arshanapalli","year":"2015","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.ard.2026.02.018_bib0005","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s40674-021-00182-1","article-title":"Inhibiting interferon pathways in dermatomyositis: rationale and preliminary evidence","volume":"7","author":"Casal-Dominguez","year":"2021","journal-title":"Curr Treatm Opt Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2026.02.018_bib0006","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.ard.2025.07.015","article-title":"Spatial transcriptomic analysis of muscle biopsy from patients with treatment-naive juvenile dermatomyositis reveals mitochondrial abnormalities despite disease-related interferon-driven signature","volume":"84","author":"Syntakas","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"10473","key":"10.1016\/j.ard.2026.02.018_bib0007","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(24)02071-3","article-title":"Efficacy, safety, and target engagement of dazukibart, an IFN\u03b2 specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Fiorentino","year":"2025","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ard.2026.02.018_bib0008","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.ard.2026.02.018_bib0009","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/rheumatology\/kew213","article-title":"Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients","volume":"55","author":"Nagaraju","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.ard.2026.02.018_bib0010","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1084\/jem.20090247","article-title":"Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant","volume":"206","author":"Longhi","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.ard.2026.02.018_bib0011","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.gene.2018.12.059","article-title":"Gene expression profiling of porcine skeletal muscle satellite cells after poly(I:C) stimulation","volume":"695","author":"TN","year":"2019","journal-title":"Gene"},{"issue":"9","key":"10.1016\/j.ard.2026.02.018_bib0012","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1002\/art.38038","article-title":"Interferon-\u03b1 induction and detection of anti-ro, anti-la, anti-sm, and anti-rnp autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis","volume":"65","author":"Balboni","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.ard.2026.02.018_bib0013","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1136\/ard-2024-225912","article-title":"Serum from patients with idiopathic inflammatory myopathy induces skeletal muscle weakness","volume":"83","author":"Leijding","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.018_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.106051","article-title":"High-intensity interval training outperforms moderate exercise to improve aerobic capacity in patients with recent-onset idiopathic inflammatory myopathies: a multicentre randomised controlled trial","volume":"122","author":"Andreasson","year":"2025","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.ard.2026.02.018_bib0015","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1002\/art.23963","article-title":"Reliability and validity of the myositis disease activity assessment tool","volume":"58","author":"Sultan","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2026.02.018_bib0016","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13395-018-0160-3","article-title":"Characterization and utilization of the flexor digitorum brevis for assessing skeletal muscle function","volume":"8","author":"Tarpey","year":"2018","journal-title":"Skelet Muscle"},{"issue":"12","key":"10.1016\/j.ard.2026.02.018_bib0017","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1113\/JP277456","article-title":"Intact single muscle fibres from SOD1G93A amyotrophic lateral sclerosis mice display preserved specific force, fatigue resistance and training-like adaptations","volume":"597","author":"Cheng","year":"2019","journal-title":"J Physiol"},{"issue":"4","key":"10.1016\/j.ard.2026.02.018_bib0018","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat Methods"},{"issue":"7","key":"10.1016\/j.ard.2026.02.018_bib0019","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"10.1016\/j.ard.2026.02.018_bib0020","doi-asserted-by":"crossref","first-page":"W415","DOI":"10.1093\/nar\/gkae456","article-title":"WebGestalt 2024: faster gene set analysis and new support for metabolomics and multi-omics","volume":"52","author":"Elizarraras","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"21","key":"10.1016\/j.ard.2026.02.018_bib0021","doi-asserted-by":"crossref","first-page":"e2108","DOI":"10.1212\/WNL.0000000000200271","article-title":"Involvement of type I interferon signaling in muscle stem cell proliferation during dermatomyositis","volume":"98","author":"Gallay","year":"2022","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.ard.2026.02.018_bib0022","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1093\/brain\/awaf153","article-title":"Interferon-\u03b3 causes myogenic cell dysfunction and senescence in immune myopathies","volume":"148","author":"Hou","year":"2025","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.ard.2026.02.018_bib0023","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.ard.2026.02.018_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.899569","article-title":"Pycard and BC017158 candidate genes of Irm1 locus modulate inflammasome activation for IL-1\u03b2 production","volume":"13","author":"Borrego","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.ard.2026.02.018_bib0025","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.chom.2020.09.014","article-title":"RTP4 is a potent IFN-inducible anti-flavivirus effector engaged in a host-virus arms race in bats and other mammals","volume":"28","author":"Boys","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ard.2026.02.018_bib0026","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3389\/fcimb.2017.00196","article-title":"The association of OASL and type I interferons in the pathogenesis and survival of intracellular replicating bacterial species","volume":"7","author":"Leisching","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"issue":"8","key":"10.1016\/j.ard.2026.02.018_bib0027","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1002\/cam4.3846","article-title":"MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy","volume":"10","author":"Juraleviciute","year":"2021","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.ard.2026.02.018_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133190","article-title":"The interferon-inducible mouse apolipoprotein L9 and prohibitins cooperate to restrict Theiler\u2019s virus replication","volume":"10","author":"Kreit","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ard.2026.02.018_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114221","article-title":"A ZBP1 isoform blocks ZBP1-mediated cell death","volume":"43","author":"Cai","year":"2024","journal-title":"Cell Rep"},{"issue":"9","key":"10.1016\/j.ard.2026.02.018_bib0030","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/eji.201242653","article-title":"IL-17: a new actor in IFN-driven systemic autoimmune diseases","volume":"42","author":"Ambrosi","year":"2012","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.ard.2026.02.018_bib0031","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1089\/jir.2011.0028","article-title":"The role of nuclear factor \u03baB in the interferon response","volume":"31","author":"Pfeffer","year":"2011","journal-title":"J Interferon Cytokine Res"},{"issue":"8","key":"10.1016\/j.ard.2026.02.018_bib0032","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1084\/jem.20080383","article-title":"Transcriptional role of p53 in interferon-mediated antiviral immunity","volume":"205","author":"Mu\u00f1oz-Fontela","year":"2008","journal-title":"J Exp Med"},{"issue":"5231","key":"10.1016\/j.ard.2026.02.018_bib0033","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1126\/science.7569900","article-title":"Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins","volume":"269","author":"David","year":"1995","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ard.2026.02.018_bib0034","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41598-017-18308-8","article-title":"A central role for PI3K-AKT signaling pathway in linking SAMHD1-deficiency to the type I interferon signature","volume":"8","author":"Oh","year":"2018","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.ard.2026.02.018_bib0035","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-alpha in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"7","key":"10.1016\/j.ard.2026.02.018_bib0036","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.autrev.2005.03.006","article-title":"Transforming growth factor beta (TGF-beta) and autoimmunity","volume":"4","author":"Aoki","year":"2005","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.ard.2026.02.018_bib0037","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.immuni.2016.06.006","article-title":"Type 1 interferons induce changes in core metabolism that are critical for immune function","volume":"44","author":"Wu","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ard.2026.02.018_bib0038","article-title":"Interferon receptor trafficking and signaling: journey to the cross roads","volume":"11","author":"Zanin","year":"2020","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.ard.2026.02.018_bib0039","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ard.2026.02.018_bib0040","doi-asserted-by":"crossref","first-page":"855","DOI":"10.4049\/immunohorizons.2100088","article-title":"Type I IFN-driven immune cell dysregulation in rat autoimmune diabetes","volume":"5","author":"Qaisar","year":"2021","journal-title":"Immunohorizons"},{"issue":"1","key":"10.1016\/j.ard.2026.02.018_bib0041","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2337\/db16-0462","article-title":"A critical role for the type I interferon receptor in virus-induced autoimmune diabetes in rats","volume":"66","author":"Qaisar","year":"2017","journal-title":"Diabetes"},{"issue":"13","key":"10.1016\/j.ard.2026.02.018_bib0042","doi-asserted-by":"crossref","first-page":"eabb8087","DOI":"10.1126\/sciadv.abb8087","article-title":"IFNAR1 signaling in NK cells promotes persistent virus infection","volume":"7","author":"Huang","year":"2021","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.ard.2026.02.018_bib0043","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000261","article-title":"Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus","volume":"5","author":"Riggs","year":"2018","journal-title":"Lupus Sci Med"},{"issue":"2","key":"10.1016\/j.ard.2026.02.018_bib0044","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2026.02.018_bib0045","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/fon.11.81","article-title":"Ruxolitinib: a new JAK1\/2 inhibitor that offers promising options for treatment of myelofibrosis","volume":"7","author":"Ostojic","year":"2011","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.ard.2026.02.018_bib0046","first-page":"348","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.02.018_bib0047","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/rheumatology\/kead186","article-title":"Effect of type I interferon on engineered pediatric skeletal muscle: a promising model for juvenile dermatomyositis","volume":"63","author":"Covert","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.ard.2026.02.018_bib0048","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.ard.2026.02.018_bib0049","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1146\/annurev-biochem-032620-104401","article-title":"Mitochondrial DNA release in innate immune signaling","volume":"92","author":"Newman","year":"2023","journal-title":"Annu Rev Biochem"},{"issue":"9","key":"10.1016\/j.ard.2026.02.018_bib0050","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202050051","article-title":"Autoimmunity gene IRGM suppresses cGAS-STING and RIG-I-MAVS signaling to control interferon response","volume":"21","author":"Jena","year":"2020","journal-title":"EMBO Rep"},{"issue":"1","key":"10.1016\/j.ard.2026.02.018_bib0051","doi-asserted-by":"crossref","DOI":"10.1080\/08916934.2023.2220984","article-title":"Patients with dermatomyositis shared partially similar transcriptome signature with COVID-19 infection","volume":"56","author":"Yang","year":"2023","journal-title":"Autoimmunity"},{"issue":"2","key":"10.1016\/j.ard.2026.02.018_bib0052","doi-asserted-by":"crossref","first-page":"275","DOI":"10.31138\/mjr.34.2.275","article-title":"The role of myositis-specific and myositis-associated autoantibodies and the activation of type I interferon pathway in the generation of clinical phenotypes of inflammatory myopathies","volume":"34","author":"Skarlis","year":"2023","journal-title":"Mediterr J Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.02.018_bib0053","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","article-title":"TGF-\u03b2 signaling in health, disease, and therapeutics","volume":"9","author":"Deng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.ard.2026.02.018_bib0054","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cyto.2012.07.011","article-title":"Pilot study of interleukin-27 in pathogenesis of dermatomyositis and polymyositis: associated with interstitial lung diseases","volume":"60","author":"Shen","year":"2012","journal-title":"Cytokine"},{"issue":"12","key":"10.1016\/j.ard.2026.02.018_bib0055","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1093\/rheumatology\/key222","article-title":"Expression of interleukin-18 in muscle tissue of patients with polymyositis or dermatomyositis and effects of conventional immunosuppressive treatment","volume":"57","author":"Helmers","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.ard.2026.02.018_bib0056","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.semarthrit.2020.05.008","article-title":"The altered metabolism profile in pathogenesis of idiopathic inflammatory myopathies","volume":"50","author":"Liu","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.ard.2026.02.018_bib0057","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1002\/art.42615","article-title":"Shared and distinctive transcriptomic and proteomic pathways in adult and juvenile dermatomyositis","volume":"75","author":"Ward","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.02.018_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103522","article-title":"Sera from patients with dermatomyositis and antisynthetase syndrome mediate muscle weakness, impair mitochondrial respiration and induce local cytokine production in muscle tissue","volume":"158","author":"Leijding","year":"2026","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.ard.2026.02.018_bib0059","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1164\/rccm.2202005","article-title":"Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments","volume":"166","author":"Reid","year":"2002","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T19:51:27Z","timestamp":1780861887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726000968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0003496726000968"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.02.018","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of the type I interferon receptor pathway protects against muscle weakness induced by dermatomyositis serum","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}